RyboDyn raised $10 million in seed funding to accelerate oncology target discovery by exploring the “dark proteome,” the pool of understudied peptides and protein products not captured in standard proteomic workflows. The company’s platform, RyboCypher, pairs deep sequencing of non-canonical RNAs with proteome detection to identify disease-specific druggable targets. RyboDyn said its CypherAtlas database includes data from roughly 1,000 patient tumors across 10 cancer indications, plus information on millions of uncharacterized RNAs and tens of thousands of cryptic peptides characterized by mass spectrometry, including cancer-specific peptides. The company also reported in vitro killing tied to a cryptic protein target and identified a novel cryptic target in a substantial fraction of HER2-negative breast tumors. Investors will watch whether RyboDyn can translate cryptic target hypotheses into validated biology and early drug-like lead series that stand up to conventional target-efficiency benchmarks.